In the Thick of It Transistor (https://transistor.fm) https://feeds.transistor.fm/in-the-thick-of-it Tune into our bi-monthly podcast where we interview experts in the field to broaden the awareness of new HCM studies & advancements! 2023 Hypertrophic Cardiomyopathy Medical Society d110db2d-936c-5e73-901f-741ed6b2aa75 yes bf75b660-f319-11f0-a187-dd3f6b83660a en Mon, 09 Mar 2026 15:43:01 -0400 Mon, 09 Mar 2026 15:43:05 -0400 https://img.transistorcdn.com/mR7hGWgzHTcaYshXk1Q8A_ZwLzC_e49PhTahbOfVwjM/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzQyODczLzE3MTIw/NjY3MTUtYXJ0d29y/ay5qcGc.jpg In the Thick of It episodic Hypertrophic Cardiomyopathy Medical Society Tune into our bi-monthly podcast where we interview experts in the field to broaden the awareness of new HCM studies & advancements! Tune into our bi-monthly podcast where we interview experts in the field to broaden the awareness of new HCM studies & advancements!. Jason Gillikin contentstudio-admin@walkwest.com No No Bionic Tech and Shared Decisions: Exploring the Spectrum of ICD Care in HCM 32 32 Bionic Tech and Shared Decisions: Exploring the Spectrum of ICD Care in HCM full cb3cd029-6fce-47c8-9bb1-97ce96aafee4 https://share.transistor.fm/s/7c1d8a72 In this episode of In the Thick of It, Dr. John Fritzlen joins leading electrophysiologist Dr. Mark Link and Hannah and Bethany from Heart Charged to discuss the critical role of implantable cardioverter-defibrillators (ICDs) in managing hypertrophic cardiomyopathy. The group navigates the complex clinical landscape of ICD indications, including the importance of MRI findings and specific risk factors like non-sustained ventricular tachycardia (NSVT). Dr. Link provides an expert comparison of transvenous, subcutaneous (S-ICD), and the latest extravascular (EV-ICD) technologies, focusing on device durability and suitability for active patients. Throughout the conversation, the "Bionic Babes" of Heart Charged offer invaluable patient perspectives on life with a defibrillator, the necessity of shared decision-making, and the evolving guidelines that now encourage vigorous exercise for those living with the condition.

]]> In this episode of In the Thick of It, Dr. John Fritzlen joins leading electrophysiologist Dr. Mark Link and Hannah and Bethany from Heart Charged to discuss the critical role of implantable cardioverter-defibrillators (ICDs) in managing hypertrophic cardiomyopathy. The group navigates the complex clinical landscape of ICD indications, including the importance of MRI findings and specific risk factors like non-sustained ventricular tachycardia (NSVT). Dr. Link provides an expert comparison of transvenous, subcutaneous (S-ICD), and the latest extravascular (EV-ICD) technologies, focusing on device durability and suitability for active patients. Throughout the conversation, the "Bionic Babes" of Heart Charged offer invaluable patient perspectives on life with a defibrillator, the necessity of shared decision-making, and the evolving guidelines that now encourage vigorous exercise for those living with the condition.

]]> Mon, 22 Dec 2025 04:20:00 -0500 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1737 In this episode of In the Thick of It, Dr. John Fritzlen joins leading electrophysiologist Dr. Mark Link and Hannah and Bethany from Heart Charged to discuss the critical role of implantable cardioverter-defibrillators (ICDs) in managing hypertrophic cardiomyopathy. The group navigates the complex clinical landscape of ICD indications, including the importance of MRI findings and specific risk factors like non-sustained ventricular tachycardia (NSVT). Dr. Link provides an expert comparison of transvenous, subcutaneous (S-ICD), and the latest extravascular (EV-ICD) technologies, focusing on device durability and suitability for active patients. Throughout the conversation, the "Bionic Babes" of Heart Charged offer invaluable patient perspectives on life with a defibrillator, the necessity of shared decision-making, and the evolving guidelines that now encourage vigorous exercise for those living with the condition.

]]> No Redefining the Standard: Insights from the MAPLE Trial in Obstructive HCM 31 31 Redefining the Standard: Insights from the MAPLE Trial in Obstructive HCM full cf274f17-253d-4487-a6c4-a03ddf2eb716 https://share.transistor.fm/s/7242df36 In this episode of In the Thick of It, Dr. Floridian Rader and Dr. Ahmad Masri discuss the transformative results of the MAPLE trial, a head-to-head study comparing aficamten—a cardiac myosin inhibitor—to metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy1. The trial utilized a rigorous "double-dummy" design to ensure blinding while testing both medications at therapeutic doses2. Dr. Masri highlights unexpected findings, including the significant reduction in peak $VO_2$ and the worsening of cardiac biomarkers like NT-proBNP in the metoprolol group3. The conversation explores how these results challenge decades of reliance on beta-blockers as a first-line therapy and demonstrate the efficacy of aficamten as a potent upfront monotherapy for improving patient function and cardiac remodeling4.

]]> In this episode of In the Thick of It, Dr. Floridian Rader and Dr. Ahmad Masri discuss the transformative results of the MAPLE trial, a head-to-head study comparing aficamten—a cardiac myosin inhibitor—to metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy1. The trial utilized a rigorous "double-dummy" design to ensure blinding while testing both medications at therapeutic doses2. Dr. Masri highlights unexpected findings, including the significant reduction in peak $VO_2$ and the worsening of cardiac biomarkers like NT-proBNP in the metoprolol group3. The conversation explores how these results challenge decades of reliance on beta-blockers as a first-line therapy and demonstrate the efficacy of aficamten as a potent upfront monotherapy for improving patient function and cardiac remodeling4.

]]> Mon, 22 Dec 2025 04:11:00 -0500 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1020 In this episode of In the Thick of It, Dr. Floridian Rader and Dr. Ahmad Masri discuss the transformative results of the MAPLE trial, a head-to-head study comparing aficamten—a cardiac myosin inhibitor—to metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy1. The trial utilized a rigorous "double-dummy" design to ensure blinding while testing both medications at therapeutic doses2. Dr. Masri highlights unexpected findings, including the significant reduction in peak $VO_2$ and the worsening of cardiac biomarkers like NT-proBNP in the metoprolol group3. The conversation explores how these results challenge decades of reliance on beta-blockers as a first-line therapy and demonstrate the efficacy of aficamten as a potent upfront monotherapy for improving patient function and cardiac remodeling4.

]]> No Decoding Refractory Symptoms: Advanced Diagnosis and Management in HCM 30 30 Decoding Refractory Symptoms: Advanced Diagnosis and Management in HCM full 36f46be0-6b28-4975-995e-27294211f886 https://share.transistor.fm/s/bc66c0e2 In this episode of In the Thick of It, Dr. Madeline Smoot talks with Dr. Alex McNamara to discuss the complexities of managing refractory symptoms in patients with hypertrophic cardiomyopathy (HCM). The conversation highlights the distinction between obstructive and non-obstructive symptoms, emphasizing the importance of provocative testing—such as cardiopulmonary exercise testing (CPET) and gold-directed Valsalva maneuvers—to unmask "labile" obstruction that resting echoes might miss. They explore the evolving role of cardiac myosin inhibitors and the potential impact of GLP-1 agonists on obesity-related symptom burden. Additionally, Dr. McNamara provides insights into identifying red flags beyond obstruction, including primary mitral valve disease and the early stages of restrictive or "burnt-out" HCM.

]]> In this episode of In the Thick of It, Dr. Madeline Smoot talks with Dr. Alex McNamara to discuss the complexities of managing refractory symptoms in patients with hypertrophic cardiomyopathy (HCM). The conversation highlights the distinction between obstructive and non-obstructive symptoms, emphasizing the importance of provocative testing—such as cardiopulmonary exercise testing (CPET) and gold-directed Valsalva maneuvers—to unmask "labile" obstruction that resting echoes might miss. They explore the evolving role of cardiac myosin inhibitors and the potential impact of GLP-1 agonists on obesity-related symptom burden. Additionally, Dr. McNamara provides insights into identifying red flags beyond obstruction, including primary mitral valve disease and the early stages of restrictive or "burnt-out" HCM.

]]> Mon, 22 Dec 2025 04:07:00 -0500 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1282 In this episode of In the Thick of It, Dr. Madeline Smoot talks with Dr. Alex McNamara to discuss the complexities of managing refractory symptoms in patients with hypertrophic cardiomyopathy (HCM). The conversation highlights the distinction between obstructive and non-obstructive symptoms, emphasizing the importance of provocative testing—such as cardiopulmonary exercise testing (CPET) and gold-directed Valsalva maneuvers—to unmask "labile" obstruction that resting echoes might miss. They explore the evolving role of cardiac myosin inhibitors and the potential impact of GLP-1 agonists on obesity-related symptom burden. Additionally, Dr. McNamara provides insights into identifying red flags beyond obstruction, including primary mitral valve disease and the early stages of restrictive or "burnt-out" HCM.

]]> No The "Neglected Middle": Redefining HCM Genetics with Intermediate Effect Variants 29 29 The "Neglected Middle": Redefining HCM Genetics with Intermediate Effect Variants full 904d5e6c-7dfa-4f15-93f3-42c56f42ca6e https://share.transistor.fm/s/89e2b5ec In this episode of In the Thick of It, genetic counselor Matthew Thomas sits down with Dr. Roddy Walsh and Dr. Juan Pablo Ochoa to discuss their groundbreaking research on the genetic architecture of Hypertrophic Cardiomyopathy (HCM). The conversation centers on "Intermediate Effect Variants" (IEVs)—genetic markers that fall between rare, high-impact Mendelian mutations and common, low-impact polygenic risk factors. By utilizing a massive dataset of over 20,000 patients and robust ancestry-matched controls, the researchers demonstrate how these variants contribute to disease severity, age of onset, and wall thickness. This episode explores the practical implications for clinical genetic testing, the necessity of diverse genomic data, and how these findings are shifting the field toward a more quantitative and comprehensive understanding of HCM risk.

References: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.125.074529

]]> In this episode of In the Thick of It, genetic counselor Matthew Thomas sits down with Dr. Roddy Walsh and Dr. Juan Pablo Ochoa to discuss their groundbreaking research on the genetic architecture of Hypertrophic Cardiomyopathy (HCM). The conversation centers on "Intermediate Effect Variants" (IEVs)—genetic markers that fall between rare, high-impact Mendelian mutations and common, low-impact polygenic risk factors. By utilizing a massive dataset of over 20,000 patients and robust ancestry-matched controls, the researchers demonstrate how these variants contribute to disease severity, age of onset, and wall thickness. This episode explores the practical implications for clinical genetic testing, the necessity of diverse genomic data, and how these findings are shifting the field toward a more quantitative and comprehensive understanding of HCM risk.

References: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.125.074529

]]> Mon, 22 Dec 2025 04:02:00 -0500 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1750 In this episode of In the Thick of It, genetic counselor Matthew Thomas sits down with Dr. Roddy Walsh and Dr. Juan Pablo Ochoa to discuss their groundbreaking research on the genetic architecture of Hypertrophic Cardiomyopathy (HCM). The conversation centers on "Intermediate Effect Variants" (IEVs)—genetic markers that fall between rare, high-impact Mendelian mutations and common, low-impact polygenic risk factors. By utilizing a massive dataset of over 20,000 patients and robust ancestry-matched controls, the researchers demonstrate how these variants contribute to disease severity, age of onset, and wall thickness. This episode explores the practical implications for clinical genetic testing, the necessity of diverse genomic data, and how these findings are shifting the field toward a more quantitative and comprehensive understanding of HCM risk.

References: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.125.074529

]]> No The Center of Excellence: Redefining Specialized Care in HCM 28 28 The Center of Excellence: Redefining Specialized Care in HCM full 314ad263-3aae-4730-8e02-21ec63ea1242 https://share.transistor.fm/s/737a972c In this episode of In the Thick of It, Dr. Betty Raman interviews Dr. Srihari Naidu, Director of the Hypertrophic Cardiomyopathy Medical Center at Westchester Medical Center, to explore what truly defines a "Center of Excellence". Dr. Naidu shares how his philosophy has evolved from a structural focus on advanced imaging and surgical tools to a patient-centered approach that prioritizes individualized care and a multidisciplinary "heart team". The discussion highlights the critical role of specialized centers in navigating complex differential diagnoses—such as amyloidosis or mitochondrial HCM—and the importance of shared decision-making in sudden cardiac death risk stratification. Dr. Naidu also provides a practical roadmap for clinicians looking to establish regional HCM services, emphasizing the necessity of robust echo protocols and strong collaborative networks for advanced procedures.

]]> In this episode of In the Thick of It, Dr. Betty Raman interviews Dr. Srihari Naidu, Director of the Hypertrophic Cardiomyopathy Medical Center at Westchester Medical Center, to explore what truly defines a "Center of Excellence". Dr. Naidu shares how his philosophy has evolved from a structural focus on advanced imaging and surgical tools to a patient-centered approach that prioritizes individualized care and a multidisciplinary "heart team". The discussion highlights the critical role of specialized centers in navigating complex differential diagnoses—such as amyloidosis or mitochondrial HCM—and the importance of shared decision-making in sudden cardiac death risk stratification. Dr. Naidu also provides a practical roadmap for clinicians looking to establish regional HCM services, emphasizing the necessity of robust echo protocols and strong collaborative networks for advanced procedures.

]]> Mon, 22 Dec 2025 04:00:00 -0500 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1657 In this episode of In the Thick of It, Dr. Betty Raman interviews Dr. Srihari Naidu, Director of the Hypertrophic Cardiomyopathy Medical Center at Westchester Medical Center, to explore what truly defines a "Center of Excellence". Dr. Naidu shares how his philosophy has evolved from a structural focus on advanced imaging and surgical tools to a patient-centered approach that prioritizes individualized care and a multidisciplinary "heart team". The discussion highlights the critical role of specialized centers in navigating complex differential diagnoses—such as amyloidosis or mitochondrial HCM—and the importance of shared decision-making in sudden cardiac death risk stratification. Dr. Naidu also provides a practical roadmap for clinicians looking to establish regional HCM services, emphasizing the necessity of robust echo protocols and strong collaborative networks for advanced procedures.

]]> No Metabolic Modulation in Non-Obstructive HCM: Exploring the FORTITUDE Trial 27 27 Metabolic Modulation in Non-Obstructive HCM: Exploring the FORTITUDE Trial full f0f9ac29-b30f-4ced-a0fe-52f2b089b81b https://share.transistor.fm/s/02763848 In this episode of In the Thick of It, hosts Dr. Betty Raman and Dr. James MacNamara welcome Professor Martin Maron, Director of the Hypertrophic Cardiomyopathy Center at Lahey Hospital & Medical Center, to discuss the innovative FORTITUDE-HCM study. This Phase 2b trial focuses on the symptomatic non-obstructive HCM population—a group considered to have one of the greatest unmet treatment needs in the field. The conversation explores the unique mechanism of ninerafaxstat, a metabolic modulator that shifts energy utilization from fatty acids to glucose to improve cardiac energetics and diastolic relaxation. Professor Maron highlights the promising results from the earlier IMPROVE-HCM trial, details the 12-week design of the current study, and speculates on a future where "combination therapy" becomes the standard of care for complex HCM cases.

]]> In this episode of In the Thick of It, hosts Dr. Betty Raman and Dr. James MacNamara welcome Professor Martin Maron, Director of the Hypertrophic Cardiomyopathy Center at Lahey Hospital & Medical Center, to discuss the innovative FORTITUDE-HCM study. This Phase 2b trial focuses on the symptomatic non-obstructive HCM population—a group considered to have one of the greatest unmet treatment needs in the field. The conversation explores the unique mechanism of ninerafaxstat, a metabolic modulator that shifts energy utilization from fatty acids to glucose to improve cardiac energetics and diastolic relaxation. Professor Maron highlights the promising results from the earlier IMPROVE-HCM trial, details the 12-week design of the current study, and speculates on a future where "combination therapy" becomes the standard of care for complex HCM cases.

]]> Mon, 22 Dec 2025 04:00:00 -0500 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1228 In this episode of In the Thick of It, hosts Dr. Betty Raman and Dr. James MacNamara welcome Professor Martin Maron, Director of the Hypertrophic Cardiomyopathy Center at Lahey Hospital & Medical Center, to discuss the innovative FORTITUDE-HCM study. This Phase 2b trial focuses on the symptomatic non-obstructive HCM population—a group considered to have one of the greatest unmet treatment needs in the field. The conversation explores the unique mechanism of ninerafaxstat, a metabolic modulator that shifts energy utilization from fatty acids to glucose to improve cardiac energetics and diastolic relaxation. Professor Maron highlights the promising results from the earlier IMPROVE-HCM trial, details the 12-week design of the current study, and speculates on a future where "combination therapy" becomes the standard of care for complex HCM cases.

]]> No The SONATA Trial: SGLT2 Inhibition as a New Frontier in HCM Treatment 26 26 The SONATA Trial: SGLT2 Inhibition as a New Frontier in HCM Treatment full c1f4e5fc-25c9-4188-8504-fd3e12a9a724 https://share.transistor.fm/s/b94772e6 In this episode of In the Thick of It, Dr. James MacNamara sits down with Dr. Sharlene Day, Director of Translational Research at the University of Pennsylvania, to discuss the groundbreaking SONATA trial. This double-blind, placebo-controlled clinical trial is evaluating the safety and efficacy of sotagliflozin—a dual SGLT1 and SGLT2 inhibitor—in patients with both obstructive and non-obstructive hypertrophic cardiomyopathy. Dr. Day details the trial's unique design, its primary endpoint of improving the Kansas City Cardiomyopathy Questionnaire (KCCQ) score, and the fascinating metabolic mechanisms that may allow these drugs to reduce the heart's workload. The conversation also covers the safety protocols for monitoring outflow tract obstruction and the potential pleiotropic benefits of SGLT2 inhibitors beyond traditional heart failure management.

]]> In this episode of In the Thick of It, Dr. James MacNamara sits down with Dr. Sharlene Day, Director of Translational Research at the University of Pennsylvania, to discuss the groundbreaking SONATA trial. This double-blind, placebo-controlled clinical trial is evaluating the safety and efficacy of sotagliflozin—a dual SGLT1 and SGLT2 inhibitor—in patients with both obstructive and non-obstructive hypertrophic cardiomyopathy. Dr. Day details the trial's unique design, its primary endpoint of improving the Kansas City Cardiomyopathy Questionnaire (KCCQ) score, and the fascinating metabolic mechanisms that may allow these drugs to reduce the heart's workload. The conversation also covers the safety protocols for monitoring outflow tract obstruction and the potential pleiotropic benefits of SGLT2 inhibitors beyond traditional heart failure management.

]]> Mon, 22 Dec 2025 04:00:00 -0500 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1077 In this episode of In the Thick of It, Dr. James MacNamara sits down with Dr. Sharlene Day, Director of Translational Research at the University of Pennsylvania, to discuss the groundbreaking SONATA trial. This double-blind, placebo-controlled clinical trial is evaluating the safety and efficacy of sotagliflozin—a dual SGLT1 and SGLT2 inhibitor—in patients with both obstructive and non-obstructive hypertrophic cardiomyopathy. Dr. Day details the trial's unique design, its primary endpoint of improving the Kansas City Cardiomyopathy Questionnaire (KCCQ) score, and the fascinating metabolic mechanisms that may allow these drugs to reduce the heart's workload. The conversation also covers the safety protocols for monitoring outflow tract obstruction and the potential pleiotropic benefits of SGLT2 inhibitors beyond traditional heart failure management.

]]> No Teamwork, Tech, and Tomorrow: Highlights from the 2025 Scientific Sessions 25 25 Teamwork, Tech, and Tomorrow: Highlights from the 2025 Scientific Sessions full f9f2b1ea-4372-416a-a247-c893823a7ae9 https://share.transistor.fm/s/69640160 Dr. James MacNamara and Dr. Betty Raman recap the latest annual Hypertrophic Cardiomyopathy Society (HCMS) meeting held in New Orleans. The discussion emphasizes that HCM care is a "team sport," involving a multidisciplinary coalition of physicians, pharmacists, and advanced practice providers. Key highlights include a deep dive into Professor Hugh Watkins' lecture on the future of gene therapy and the impact of polygenic risk scores on disease penetrance. They also explore the evolving landscape of HCM treatment—comparing the roles of cardiac myosin inhibitors versus surgical interventions—and share promising new data on the safety and efficacy of moderate-intensity exercise for non-obstructive patients.

]]> Dr. James MacNamara and Dr. Betty Raman recap the latest annual Hypertrophic Cardiomyopathy Society (HCMS) meeting held in New Orleans. The discussion emphasizes that HCM care is a "team sport," involving a multidisciplinary coalition of physicians, pharmacists, and advanced practice providers. Key highlights include a deep dive into Professor Hugh Watkins' lecture on the future of gene therapy and the impact of polygenic risk scores on disease penetrance. They also explore the evolving landscape of HCM treatment—comparing the roles of cardiac myosin inhibitors versus surgical interventions—and share promising new data on the safety and efficacy of moderate-intensity exercise for non-obstructive patients.

]]> Mon, 22 Dec 2025 04:00:00 -0500 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1191 Dr. James MacNamara and Dr. Betty Raman recap the latest annual Hypertrophic Cardiomyopathy Society (HCMS) meeting held in New Orleans. The discussion emphasizes that HCM care is a "team sport," involving a multidisciplinary coalition of physicians, pharmacists, and advanced practice providers. Key highlights include a deep dive into Professor Hugh Watkins' lecture on the future of gene therapy and the impact of polygenic risk scores on disease penetrance. They also explore the evolving landscape of HCM treatment—comparing the roles of cardiac myosin inhibitors versus surgical interventions—and share promising new data on the safety and efficacy of moderate-intensity exercise for non-obstructive patients.

]]> No Seeing HCM Clearly: Optimizing Echocardiography for Better Diagnosis 24 24 Seeing HCM Clearly: Optimizing Echocardiography for Better Diagnosis full 84fb09e4-bd39-4ccd-85d0-06199a32a229 https://share.transistor.fm/s/8152bc83 How can echocardiographers improve the accuracy and confidence of hypertrophic cardiomyopathy diagnosis? In this episode of In the Thick of It, sonographers Amy Dillenbeck and Brad Mehl explore the essential role of echocardiography in evaluating HCM, sharing best practices for optimizing imaging techniques, Doppler assessment, and contrast use. They discuss the most common challenges in detecting HCM, how to train sonographers to recognize subtle diagnostic clues, and strategies to avoid misinterpretation. Whether you're a seasoned clinician or new to HCM imaging, this episode offers valuable insights into refining echocardiographic evaluation for better patient outcomes.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> How can echocardiographers improve the accuracy and confidence of hypertrophic cardiomyopathy diagnosis? In this episode of In the Thick of It, sonographers Amy Dillenbeck and Brad Mehl explore the essential role of echocardiography in evaluating HCM, sharing best practices for optimizing imaging techniques, Doppler assessment, and contrast use. They discuss the most common challenges in detecting HCM, how to train sonographers to recognize subtle diagnostic clues, and strategies to avoid misinterpretation. Whether you're a seasoned clinician or new to HCM imaging, this episode offers valuable insights into refining echocardiographic evaluation for better patient outcomes.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> Fri, 28 Feb 2025 07:00:00 -0500 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 2022 How can echocardiographers improve the accuracy and confidence of hypertrophic cardiomyopathy diagnosis? In this episode of In the Thick of It, sonographers Amy Dillenbeck and Brad Mehl explore the essential role of echocardiography in evaluating HCM, sharing best practices for optimizing imaging techniques, Doppler assessment, and contrast use. They discuss the most common challenges in detecting HCM, how to train sonographers to recognize subtle diagnostic clues, and strategies to avoid misinterpretation. Whether you're a seasoned clinician or new to HCM imaging, this episode offers valuable insights into refining echocardiographic evaluation for better patient outcomes.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> No Understanding NSVT: Risk Assessment and ICD Decisions in HCM 23 23 Understanding NSVT: Risk Assessment and ICD Decisions in HCM full 89a41ff7-fe27-4f17-b4b6-c0d0289a693d https://share.transistor.fm/s/b9d96500 How do we determine which hypertrophic cardiomyopathy patients are at the highest risk for sudden cardiac death? In this episode of In the Thick of It, Dr. Steve Ommen and Dr. Mark Link take a deep dive into the role of non-sustained ventricular tachycardia (NSVT) in risk assessment and ICD decision-making. They discuss how age, VT duration, and other clinical factors influence risk stratification, as well as the evolving guidelines on ICD placement. The conversation also covers the latest advancements in device technology and the nuances of selecting the right ICD for each patient. Don’t miss this essential discussion on refining risk assessment and improving outcomes in HCM care.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> How do we determine which hypertrophic cardiomyopathy patients are at the highest risk for sudden cardiac death? In this episode of In the Thick of It, Dr. Steve Ommen and Dr. Mark Link take a deep dive into the role of non-sustained ventricular tachycardia (NSVT) in risk assessment and ICD decision-making. They discuss how age, VT duration, and other clinical factors influence risk stratification, as well as the evolving guidelines on ICD placement. The conversation also covers the latest advancements in device technology and the nuances of selecting the right ICD for each patient. Don’t miss this essential discussion on refining risk assessment and improving outcomes in HCM care.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> Fri, 14 Feb 2025 06:00:00 -0500 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1197 How do we determine which hypertrophic cardiomyopathy patients are at the highest risk for sudden cardiac death? In this episode of In the Thick of It, Dr. Steve Ommen and Dr. Mark Link take a deep dive into the role of non-sustained ventricular tachycardia (NSVT) in risk assessment and ICD decision-making. They discuss how age, VT duration, and other clinical factors influence risk stratification, as well as the evolving guidelines on ICD placement. The conversation also covers the latest advancements in device technology and the nuances of selecting the right ICD for each patient. Don’t miss this essential discussion on refining risk assessment and improving outcomes in HCM care.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> No Imaging Matters: How LGE Guides HCM Management 22 22 Imaging Matters: How LGE Guides HCM Management full 5cb8b813-0582-4f98-8a58-9aa320754a81 https://share.transistor.fm/s/b4b4ea26 How can late gadolinium enhancement (LGE) on cardiac MRI help predict sudden cardiac death risk in hypertrophic cardiomyopathy? In this episode of In the Thick of It, Dr. Christopher Kramer and Dr. Raymond Chan explore the clinical significance of LGE, from its role in ICD decision-making to the challenges of scar quantification. They discuss how to differentiate true myocardial scar from artifacts, the evolving guidelines on LGE thresholds, and the implications of advanced imaging techniques for HCM management. Tune in for expert insights on integrating LGE into risk assessment and optimizing patient care.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> How can late gadolinium enhancement (LGE) on cardiac MRI help predict sudden cardiac death risk in hypertrophic cardiomyopathy? In this episode of In the Thick of It, Dr. Christopher Kramer and Dr. Raymond Chan explore the clinical significance of LGE, from its role in ICD decision-making to the challenges of scar quantification. They discuss how to differentiate true myocardial scar from artifacts, the evolving guidelines on LGE thresholds, and the implications of advanced imaging techniques for HCM management. Tune in for expert insights on integrating LGE into risk assessment and optimizing patient care.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> Fri, 31 Jan 2025 06:00:00 -0500 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1414 How can late gadolinium enhancement (LGE) on cardiac MRI help predict sudden cardiac death risk in hypertrophic cardiomyopathy? In this episode of In the Thick of It, Dr. Christopher Kramer and Dr. Raymond Chan explore the clinical significance of LGE, from its role in ICD decision-making to the challenges of scar quantification. They discuss how to differentiate true myocardial scar from artifacts, the evolving guidelines on LGE thresholds, and the implications of advanced imaging techniques for HCM management. Tune in for expert insights on integrating LGE into risk assessment and optimizing patient care.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> No Valve Disease and HCM: Predicting and Preventing Complications 21 21 Valve Disease and HCM: Predicting and Preventing Complications full 88bc1fdf-876d-423b-ac5c-5a98c43810c6 https://share.transistor.fm/s/bca9d785 How do hypertrophic cardiomyopathy and aortic valve disease intersect, and what makes managing these patients so challenging? In this episode of In the Thick of It, Dr. Srihari Naidu and Dr. Megan Coylewright explore the complexities of aortic valve replacement (TAVR) in patients with HCM. What challenges arise when HCM patients undergo aortic valve replacement, and how can these risks be mitigated? They discuss the risks of left ventricular outflow tract obstruction, strategies to optimize patient outcomes, and the importance of distinguishing HCM from other conditions like amyloidosis. Tune in to learn about the role of advanced imaging, careful patient selection, and multidisciplinary heart teams in managing these overlapping conditions effectively.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> How do hypertrophic cardiomyopathy and aortic valve disease intersect, and what makes managing these patients so challenging? In this episode of In the Thick of It, Dr. Srihari Naidu and Dr. Megan Coylewright explore the complexities of aortic valve replacement (TAVR) in patients with HCM. What challenges arise when HCM patients undergo aortic valve replacement, and how can these risks be mitigated? They discuss the risks of left ventricular outflow tract obstruction, strategies to optimize patient outcomes, and the importance of distinguishing HCM from other conditions like amyloidosis. Tune in to learn about the role of advanced imaging, careful patient selection, and multidisciplinary heart teams in managing these overlapping conditions effectively.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> Wed, 08 Jan 2025 07:00:00 -0500 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1981 How do hypertrophic cardiomyopathy and aortic valve disease intersect, and what makes managing these patients so challenging? In this episode of In the Thick of It, Dr. Srihari Naidu and Dr. Megan Coylewright explore the complexities of aortic valve replacement (TAVR) in patients with HCM. What challenges arise when HCM patients undergo aortic valve replacement, and how can these risks be mitigated? They discuss the risks of left ventricular outflow tract obstruction, strategies to optimize patient outcomes, and the importance of distinguishing HCM from other conditions like amyloidosis. Tune in to learn about the role of advanced imaging, careful patient selection, and multidisciplinary heart teams in managing these overlapping conditions effectively.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> No Cracking the Code: The Role of Genetics in HCM Diagnosis, Screening, & Treatment 20 20 Cracking the Code: The Role of Genetics in HCM Diagnosis, Screening, & Treatment full 4fef9355-6f49-4eba-adce-8fb08d80beb8 https://share.transistor.fm/s/b52498b7 How has genetic testing transformed the understanding and care of hypertrophic cardiomyopathy? In this episode of In the Thick of It, Dr. Victoria Parikh and genetic counselor Tia Moscarello from the Stanford Center for Inherited Cardiovascular Disease explore the powerful role of genetics in HCM diagnosis, family screening, and treatment. They discuss groundbreaking advancements like gene therapy, precision medicine, and the evolving understanding of variants of uncertain significance (VUS). Tune in to learn how genetic insights are driving early detection, personalized therapies, and even potential cures for HCM, offering hope for patients and their families.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> How has genetic testing transformed the understanding and care of hypertrophic cardiomyopathy? In this episode of In the Thick of It, Dr. Victoria Parikh and genetic counselor Tia Moscarello from the Stanford Center for Inherited Cardiovascular Disease explore the powerful role of genetics in HCM diagnosis, family screening, and treatment. They discuss groundbreaking advancements like gene therapy, precision medicine, and the evolving understanding of variants of uncertain significance (VUS). Tune in to learn how genetic insights are driving early detection, personalized therapies, and even potential cures for HCM, offering hope for patients and their families.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> Mon, 23 Dec 2024 07:00:00 -0500 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1817 How has genetic testing transformed the understanding and care of hypertrophic cardiomyopathy? In this episode of In the Thick of It, Dr. Victoria Parikh and genetic counselor Tia Moscarello from the Stanford Center for Inherited Cardiovascular Disease explore the powerful role of genetics in HCM diagnosis, family screening, and treatment. They discuss groundbreaking advancements like gene therapy, precision medicine, and the evolving understanding of variants of uncertain significance (VUS). Tune in to learn how genetic insights are driving early detection, personalized therapies, and even potential cures for HCM, offering hope for patients and their families.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> No From Imaging to Intervention: Navigating Apical Aneurysms in HCM 19 19 From Imaging to Intervention: Navigating Apical Aneurysms in HCM full 14548b8b-e040-406c-b16d-24556b8703d3 https://share.transistor.fm/s/1112d93f What are left ventricular apical aneurysms, and why do they pose such a high risk in hypertrophic cardiomyopathy patients? In this episode of In the Thick of It, Dr. Ethan Rowin and Dr. Jeffrey Geske delve into this rare but critical HCM phenotype. They discuss how to accurately define and detect apical aneurysms, the importance of advanced imaging techniques like contrast echocardiography and cardiac MRI, and the elevated risks of sudden cardiac death and stroke these patients face. This insightful conversation also provides insights into the evolving guidelines for ICD placement and the nuanced role of aneurysm size in risk stratification. Don’t miss this deep dive into one of HCM’s most challenging presentations.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> What are left ventricular apical aneurysms, and why do they pose such a high risk in hypertrophic cardiomyopathy patients? In this episode of In the Thick of It, Dr. Ethan Rowin and Dr. Jeffrey Geske delve into this rare but critical HCM phenotype. They discuss how to accurately define and detect apical aneurysms, the importance of advanced imaging techniques like contrast echocardiography and cardiac MRI, and the elevated risks of sudden cardiac death and stroke these patients face. This insightful conversation also provides insights into the evolving guidelines for ICD placement and the nuanced role of aneurysm size in risk stratification. Don’t miss this deep dive into one of HCM’s most challenging presentations.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> Wed, 04 Dec 2024 08:00:00 -0500 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 2300 What are left ventricular apical aneurysms, and why do they pose such a high risk in hypertrophic cardiomyopathy patients? In this episode of In the Thick of It, Dr. Ethan Rowin and Dr. Jeffrey Geske delve into this rare but critical HCM phenotype. They discuss how to accurately define and detect apical aneurysms, the importance of advanced imaging techniques like contrast echocardiography and cardiac MRI, and the elevated risks of sudden cardiac death and stroke these patients face. This insightful conversation also provides insights into the evolving guidelines for ICD placement and the nuanced role of aneurysm size in risk stratification. Don’t miss this deep dive into one of HCM’s most challenging presentations.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> No Managing HCM in Pediatric Patients: Why Early Detection Matters 18 18 Managing HCM in Pediatric Patients: Why Early Detection Matters full 7473589b-b9ce-400e-a8ab-b25d8ff642f4 https://share.transistor.fm/s/fa00698c Why is early detection of hypertrophic cardiomyopathy in children so critical for effective treatment? In this episode of In the Thick of It, Dr. Matthew Martinez sits down with pediatric cardiologist Dr. Tess Saarel to explore the unique challenges of managing HCM in young patients. They discuss the importance of personalized risk assessments, the role of genetics in tailoring care, and the collaborative efforts needed to improve outcomes in pediatric HCM. Join them for an insightful conversation on the evolving landscape of pediatric cardiology in HCM care.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> Why is early detection of hypertrophic cardiomyopathy in children so critical for effective treatment? In this episode of In the Thick of It, Dr. Matthew Martinez sits down with pediatric cardiologist Dr. Tess Saarel to explore the unique challenges of managing HCM in young patients. They discuss the importance of personalized risk assessments, the role of genetics in tailoring care, and the collaborative efforts needed to improve outcomes in pediatric HCM. Join them for an insightful conversation on the evolving landscape of pediatric cardiology in HCM care.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> Wed, 13 Nov 2024 11:35:22 -0500 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1983 Why is early detection of hypertrophic cardiomyopathy in children so critical for effective treatment? In this episode of In the Thick of It, Dr. Matthew Martinez sits down with pediatric cardiologist Dr. Tess Saarel to explore the unique challenges of managing HCM in young patients. They discuss the importance of personalized risk assessments, the role of genetics in tailoring care, and the collaborative efforts needed to improve outcomes in pediatric HCM. Join them for an insightful conversation on the evolving landscape of pediatric cardiology in HCM care.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> No Complex Layers: Screening for and Managing Comorbidities in HCM 17 17 Complex Layers: Screening for and Managing Comorbidities in HCM full 769a5ea6-f141-4dde-b396-1c0bc4ef803b https://share.transistor.fm/s/32136df5 What makes managing common conditions like hypertension and sleep apnea uniquely challenging in hypertrophic cardiomyopathy patients? In this episode of In the Thick of It, Dr. Michael Ayers and Dr. Robyn Bryde tackle the complexities of treating comorbidities such as obesity and type 2 diabetes within the context of HCM. They delve into how obstructive physiology impacts treatment choices and share key considerations for surgical clearance, all aimed at optimizing patient outcomes. Tune in for practical insights into managing the multifaceted health needs of HCM patients.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> What makes managing common conditions like hypertension and sleep apnea uniquely challenging in hypertrophic cardiomyopathy patients? In this episode of In the Thick of It, Dr. Michael Ayers and Dr. Robyn Bryde tackle the complexities of treating comorbidities such as obesity and type 2 diabetes within the context of HCM. They delve into how obstructive physiology impacts treatment choices and share key considerations for surgical clearance, all aimed at optimizing patient outcomes. Tune in for practical insights into managing the multifaceted health needs of HCM patients.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> Thu, 31 Oct 2024 12:31:33 -0400 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1913 What makes managing common conditions like hypertension and sleep apnea uniquely challenging in hypertrophic cardiomyopathy patients? In this episode of In the Thick of It, Dr. Michael Ayers and Dr. Robyn Bryde tackle the complexities of treating comorbidities such as obesity and type 2 diabetes within the context of HCM. They delve into how obstructive physiology impacts treatment choices and share key considerations for surgical clearance, all aimed at optimizing patient outcomes. Tune in for practical insights into managing the multifaceted health needs of HCM patients.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> No Understanding the Impact of Atrial Fibrillation in HCM Patients 16 16 Understanding the Impact of Atrial Fibrillation in HCM Patients full d0cddb85-ef70-432f-961c-40296641bcf2 https://share.transistor.fm/s/ff98d161 What does it take for healthcare providers to meet the unique needs of HCM patients experiencing AFib? In this episode, Dr. Ethan Rowin and Dr. Jose Joglar delve into the critical topic of atrial fibrillation (AFib) in patients with hypertrophic cardiomyopathy (HCM). They discuss the heightened risk of stroke associated with AFib, the necessity for prompt anticoagulation, and the complexities of maintaining rhythm control. Tune in to gain pivotal insights into effective treatment strategies, including anti-arrhythmic medications and left atrial appendage closure devices, and discover the importance of comprehensive care and lifestyle management to improve outcomes for HCM patients facing AFib.
 
Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> What does it take for healthcare providers to meet the unique needs of HCM patients experiencing AFib? In this episode, Dr. Ethan Rowin and Dr. Jose Joglar delve into the critical topic of atrial fibrillation (AFib) in patients with hypertrophic cardiomyopathy (HCM). They discuss the heightened risk of stroke associated with AFib, the necessity for prompt anticoagulation, and the complexities of maintaining rhythm control. Tune in to gain pivotal insights into effective treatment strategies, including anti-arrhythmic medications and left atrial appendage closure devices, and discover the importance of comprehensive care and lifestyle management to improve outcomes for HCM patients facing AFib.
 
Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> Thu, 19 Sep 2024 11:27:14 -0400 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1637 What does it take for healthcare providers to meet the unique needs of HCM patients experiencing AFib? In this episode, Dr. Ethan Rowin and Dr. Jose Joglar delve into the critical topic of atrial fibrillation (AFib) in patients with hypertrophic cardiomyopathy (HCM). They discuss the heightened risk of stroke associated with AFib, the necessity for prompt anticoagulation, and the complexities of maintaining rhythm control. Tune in to gain pivotal insights into effective treatment strategies, including anti-arrhythmic medications and left atrial appendage closure devices, and discover the importance of comprehensive care and lifestyle management to improve outcomes for HCM patients facing AFib.
 
Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> No Educating Patients and Families About Genetic Implications of HCM 15 15 Educating Patients and Families About Genetic Implications of HCM full c374e59d-a523-4277-b1db-0cdca760f3aa https://share.transistor.fm/s/a6952c3a In today’s episode of In the Thick Of It, Dr. Anna Woo is joined by Dr. Sharon Cresci for a conversation on hypertrophic cardiomyopathy and its genetic implications. What role does genetic testing play in identifying familial variants and whether inheriting a pathogenic variant will lead to disease? Learn about the importance of genetic testing, lifelong serial screening, collaborative treatment approaches, and the processes of educating patients and families about HCM. Tune in as these experts provide insights on vigilance, follow-up care, and informed decision-making in HCM management.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> In today’s episode of In the Thick Of It, Dr. Anna Woo is joined by Dr. Sharon Cresci for a conversation on hypertrophic cardiomyopathy and its genetic implications. What role does genetic testing play in identifying familial variants and whether inheriting a pathogenic variant will lead to disease? Learn about the importance of genetic testing, lifelong serial screening, collaborative treatment approaches, and the processes of educating patients and families about HCM. Tune in as these experts provide insights on vigilance, follow-up care, and informed decision-making in HCM management.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> Tue, 30 Jul 2024 16:52:36 -0400 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 2206 In today’s episode of In the Thick Of It, Dr. Anna Woo is joined by Dr. Sharon Cresci for a conversation on hypertrophic cardiomyopathy and its genetic implications. What role does genetic testing play in identifying familial variants and whether inheriting a pathogenic variant will lead to disease? Learn about the importance of genetic testing, lifelong serial screening, collaborative treatment approaches, and the processes of educating patients and families about HCM. Tune in as these experts provide insights on vigilance, follow-up care, and informed decision-making in HCM management.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> No Septal Myectomy and Mitral Valve Repair: Personalized Approaches in Treating HCM 14 14 Septal Myectomy and Mitral Valve Repair: Personalized Approaches in Treating HCM full cf139bb2-1d7d-4a8d-ab3d-27ccf237b9d5 https://share.transistor.fm/s/dc6e8c47 On today's episode of 'In The Thick of It', Dr. Benjamin Van Boxtel welcomes Dr. Daniel Swistel and Dr. Joseph Dearani to discuss Septal Myectomy and mitral valve repair. Why is personalized patient care crucial when managing hypertrophic cardiomyopathy? Tune in as these specialists explore the importance of customized procedures, teamwork across disciplines, ongoing education, and staying abreast of the latest technological advancements in the field. Dr. Swistel and Dr. Dearani also explain the significance of comprehensive evaluations and specialist collaboration in treating HCM. But what obstacles do they encounter in their multidisciplinary efforts? Check out today's episode to discover their approaches to these challenges, and to learn how the latest surgical innovations are transforming treatment options for HCM and beyond.


Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> On today's episode of 'In The Thick of It', Dr. Benjamin Van Boxtel welcomes Dr. Daniel Swistel and Dr. Joseph Dearani to discuss Septal Myectomy and mitral valve repair. Why is personalized patient care crucial when managing hypertrophic cardiomyopathy? Tune in as these specialists explore the importance of customized procedures, teamwork across disciplines, ongoing education, and staying abreast of the latest technological advancements in the field. Dr. Swistel and Dr. Dearani also explain the significance of comprehensive evaluations and specialist collaboration in treating HCM. But what obstacles do they encounter in their multidisciplinary efforts? Check out today's episode to discover their approaches to these challenges, and to learn how the latest surgical innovations are transforming treatment options for HCM and beyond.


Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> Fri, 21 Jun 2024 13:59:08 -0400 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 2905 On today's episode of 'In The Thick of It', Dr. Benjamin Van Boxtel welcomes Dr. Daniel Swistel and Dr. Joseph Dearani to discuss Septal Myectomy and mitral valve repair. Why is personalized patient care crucial when managing hypertrophic cardiomyopathy? Tune in as these specialists explore the importance of customized procedures, teamwork across disciplines, ongoing education, and staying abreast of the latest technological advancements in the field. Dr. Swistel and Dr. Dearani also explain the significance of comprehensive evaluations and specialist collaboration in treating HCM. But what obstacles do they encounter in their multidisciplinary efforts? Check out today's episode to discover their approaches to these challenges, and to learn how the latest surgical innovations are transforming treatment options for HCM and beyond.


Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> No Optimizing Treatment: The New Hypertrophic Cardiomyopathy Guidelines Explained 13 13 Optimizing Treatment: The New Hypertrophic Cardiomyopathy Guidelines Explained full 970cf51a-90d9-48d3-9ed3-c498b36f28b6 https://share.transistor.fm/s/26b07c8b On this episode of 'In The Thick of It',  Dr. Steve Ommen joins Dr. Matthew Martinez to explain the latest changes and updates to the HCM guidelines. What is the importance of personalized patient care, shared decision-making, and lifestyle adjustments for HCM patients? Find out as Dr. Martinez and Dr. Ommen discuss risk assessment methodologies, effective management strategies for atrial fibrillation, and the evolving landscape of emerging medical therapies for HCM. These seasoned experts also dissect critical information from the new guidelines while drawing attention to key similarities and differences compared to prior guidelines. What impact do these new guidelines have on individuals affected by HCM across all age brackets? Join Dr. Martinez and Dr. Ommen as they explain how these updates aim to align clinical practices with the latest evidence, ensuring personalized and effective management of HCM.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> On this episode of 'In The Thick of It',  Dr. Steve Ommen joins Dr. Matthew Martinez to explain the latest changes and updates to the HCM guidelines. What is the importance of personalized patient care, shared decision-making, and lifestyle adjustments for HCM patients? Find out as Dr. Martinez and Dr. Ommen discuss risk assessment methodologies, effective management strategies for atrial fibrillation, and the evolving landscape of emerging medical therapies for HCM. These seasoned experts also dissect critical information from the new guidelines while drawing attention to key similarities and differences compared to prior guidelines. What impact do these new guidelines have on individuals affected by HCM across all age brackets? Join Dr. Martinez and Dr. Ommen as they explain how these updates aim to align clinical practices with the latest evidence, ensuring personalized and effective management of HCM.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> Thu, 06 Jun 2024 10:31:33 -0400 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 2024 On this episode of 'In The Thick of It',  Dr. Steve Ommen joins Dr. Matthew Martinez to explain the latest changes and updates to the HCM guidelines. What is the importance of personalized patient care, shared decision-making, and lifestyle adjustments for HCM patients? Find out as Dr. Martinez and Dr. Ommen discuss risk assessment methodologies, effective management strategies for atrial fibrillation, and the evolving landscape of emerging medical therapies for HCM. These seasoned experts also dissect critical information from the new guidelines while drawing attention to key similarities and differences compared to prior guidelines. What impact do these new guidelines have on individuals affected by HCM across all age brackets? Join Dr. Martinez and Dr. Ommen as they explain how these updates aim to align clinical practices with the latest evidence, ensuring personalized and effective management of HCM.

Season 2 of In the Thick of It is brought to you by the HCM Society, is supported by sponsorship from Cytokinetics, and is produced by Earfluence.

]]> No Navigating Cardiac Myosin Therapy: Insights for NYHA Class II HCM Patients 12 12 Navigating Cardiac Myosin Therapy: Insights for NYHA Class II HCM Patients full da07f2e4-3331-4e60-a7b4-06ba19dc7572 https://share.transistor.fm/s/d403b5f6 When should we make the critical decision to start Cardiac Myosin therapy in NYHA Class II HCM patients? Today, Dr. Patrycja Galazka is joined by Dr. Sara Saberi, Assistant Associate Professor in Cardiovascular Medicine and co-director of the Inherited Cardiomyopathy Program at the Frankel Cardiovascular Center. Together, we dive into the intricate world of Cardiac Myosin Inhibitors, addressing this vital question.

In the ever-changing landscape of HCM management, this episode offers a beacon of clarity. Whether you're a healthcare professional dedicated to improving patient outcomes or someone personally navigating the challenges of HCM, our conversation provides essential insights. Join us for a discussion that could reshape your approach to HCM care.

In the Thick of It is brought to you by the HCM Society and is produced by Earfluence.

]]> When should we make the critical decision to start Cardiac Myosin therapy in NYHA Class II HCM patients? Today, Dr. Patrycja Galazka is joined by Dr. Sara Saberi, Assistant Associate Professor in Cardiovascular Medicine and co-director of the Inherited Cardiomyopathy Program at the Frankel Cardiovascular Center. Together, we dive into the intricate world of Cardiac Myosin Inhibitors, addressing this vital question.

In the ever-changing landscape of HCM management, this episode offers a beacon of clarity. Whether you're a healthcare professional dedicated to improving patient outcomes or someone personally navigating the challenges of HCM, our conversation provides essential insights. Join us for a discussion that could reshape your approach to HCM care.

In the Thick of It is brought to you by the HCM Society and is produced by Earfluence.

]]> Wed, 13 Mar 2024 09:50:58 -0400 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 2315 When should we make the critical decision to start Cardiac Myosin therapy in NYHA Class II HCM patients? Today, Dr. Patrycja Galazka is joined by Dr. Sara Saberi, Assistant Associate Professor in Cardiovascular Medicine and co-director of the Inherited Cardiomyopathy Program at the Frankel Cardiovascular Center. Together, we dive into the intricate world of Cardiac Myosin Inhibitors, addressing this vital question.

In the ever-changing landscape of HCM management, this episode offers a beacon of clarity. Whether you're a healthcare professional dedicated to improving patient outcomes or someone personally navigating the challenges of HCM, our conversation provides essential insights. Join us for a discussion that could reshape your approach to HCM care.

In the Thick of It is brought to you by the HCM Society and is produced by Earfluence.

]]> No Gene Therapy and the Future of Heart Health: A Conversation with Dr. Sharlene Day and Dr. Carolyn Ho 11 11 Gene Therapy and the Future of Heart Health: A Conversation with Dr. Sharlene Day and Dr. Carolyn Ho full 1bf6843b-749e-408a-af36-73b24c39e2f6 https://share.transistor.fm/s/77b8af69 How do you envision the role of gene therapy in shaping the future of cardiac care? In today’s episode, your host, Dr. Sharlene Day, engages in an enlightening conversation with Dr. Carolyn Ho, delving into the transformative world of gene therapy. Together, they navigate the complexities of gene therapy's fundamental concepts and potential applications in treating genetic cardiomyopathies and arrhythmia syndromes.

Remember, understanding the potential of gene therapy is just the beginning. Collectively, we can pave the way for transformative advancements in treating genetic heart conditions by staying informed and engaged.

In the Thick of It is brought to you by the HCM Society and is produced by Earfluence.

]]> How do you envision the role of gene therapy in shaping the future of cardiac care? In today’s episode, your host, Dr. Sharlene Day, engages in an enlightening conversation with Dr. Carolyn Ho, delving into the transformative world of gene therapy. Together, they navigate the complexities of gene therapy's fundamental concepts and potential applications in treating genetic cardiomyopathies and arrhythmia syndromes.

Remember, understanding the potential of gene therapy is just the beginning. Collectively, we can pave the way for transformative advancements in treating genetic heart conditions by staying informed and engaged.

In the Thick of It is brought to you by the HCM Society and is produced by Earfluence.

]]> Wed, 28 Feb 2024 00:00:00 -0500 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1583 How do you envision the role of gene therapy in shaping the future of cardiac care? In today’s episode, your host, Dr. Sharlene Day, engages in an enlightening conversation with Dr. Carolyn Ho, delving into the transformative world of gene therapy. Together, they navigate the complexities of gene therapy's fundamental concepts and potential applications in treating genetic cardiomyopathies and arrhythmia syndromes.

Remember, understanding the potential of gene therapy is just the beginning. Collectively, we can pave the way for transformative advancements in treating genetic heart conditions by staying informed and engaged.

In the Thick of It is brought to you by the HCM Society and is produced by Earfluence.

]]> No Advancements in Nonobstructive HCM: A Discussion with Dr. Michelle Kittleson 10 10 Advancements in Nonobstructive HCM: A Discussion with Dr. Michelle Kittleson full 9d416d1d-6617-433e-a3e6-a9843b0c068e https://share.transistor.fm/s/663bf3bb Are the symptoms of nonobstructive hypertrophic cardiomyopathy (nHCM) holding patients back from living their fullest lives? Join Dr. Melissa Lyle and Dr. Michelle Kittleson as they unravel the mysteries of nHCM symptoms like congestion, angina, and exercise intolerance. How can we better manage these symptoms and pave the way for improved quality of life?

Tune in as they explore innovative solutions, from advanced therapies to cutting-edge gene editing technologies like CRISPR, in the quest for better patient outcomes. Let's uncover the path to empowerment for nHCM patients together.

In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.

]]> Are the symptoms of nonobstructive hypertrophic cardiomyopathy (nHCM) holding patients back from living their fullest lives? Join Dr. Melissa Lyle and Dr. Michelle Kittleson as they unravel the mysteries of nHCM symptoms like congestion, angina, and exercise intolerance. How can we better manage these symptoms and pave the way for improved quality of life?

Tune in as they explore innovative solutions, from advanced therapies to cutting-edge gene editing technologies like CRISPR, in the quest for better patient outcomes. Let's uncover the path to empowerment for nHCM patients together.

In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.

]]> Wed, 14 Feb 2024 00:00:00 -0500 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1132 Are the symptoms of nonobstructive hypertrophic cardiomyopathy (nHCM) holding patients back from living their fullest lives? Join Dr. Melissa Lyle and Dr. Michelle Kittleson as they unravel the mysteries of nHCM symptoms like congestion, angina, and exercise intolerance. How can we better manage these symptoms and pave the way for improved quality of life?

Tune in as they explore innovative solutions, from advanced therapies to cutting-edge gene editing technologies like CRISPR, in the quest for better patient outcomes. Let's uncover the path to empowerment for nHCM patients together.

In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.

]]> No Imaging in HCM with Dr. Caroline Coats & James Moon 9 9 Imaging in HCM with Dr. Caroline Coats & James Moon full 59209cca-ec3d-4292-8698-6798ecbbdd40 https://share.transistor.fm/s/dc1d5d4e In today’s episode, Cardiologist Dr. Caroline Coats is talking with with Dr. James Moon, the CEO of Mycardium AI Ltd, and a distinguished Professor of Cardiology at University College London.  Dr. Moon’s groundbreaking work in cardiac MRI, especially in hypertrophic cardiomyopathy, has changed the way professionals understand and diagnose heart conditions. Today, we’re delving into his wealth of knowledge and experience on imaging in HCM. If you're ready to unlock the secrets of the heart and explore the cutting-edge developments in cardiology, stay tuned.

In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.


]]> In today’s episode, Cardiologist Dr. Caroline Coats is talking with with Dr. James Moon, the CEO of Mycardium AI Ltd, and a distinguished Professor of Cardiology at University College London.  Dr. Moon’s groundbreaking work in cardiac MRI, especially in hypertrophic cardiomyopathy, has changed the way professionals understand and diagnose heart conditions. Today, we’re delving into his wealth of knowledge and experience on imaging in HCM. If you're ready to unlock the secrets of the heart and explore the cutting-edge developments in cardiology, stay tuned.

In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.


]]> Wed, 01 Nov 2023 00:42:00 -0400 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1532 In today’s episode, Cardiologist Dr. Caroline Coats is talking with with Dr. James Moon, the CEO of Mycardium AI Ltd, and a distinguished Professor of Cardiology at University College London.  Dr. Moon’s groundbreaking work in cardiac MRI, especially in hypertrophic cardiomyopathy, has changed the way professionals understand and diagnose heart conditions. Today, we’re delving into his wealth of knowledge and experience on imaging in HCM. If you're ready to unlock the secrets of the heart and explore the cutting-edge developments in cardiology, stay tuned.

In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.


]]> No Unlocking Heart Health: Dr. Ayers & Dr. Owens on Myosin Inhibitors 8 8 Unlocking Heart Health: Dr. Ayers & Dr. Owens on Myosin Inhibitors full 6576c8cb-0c2c-453f-8425-692287fb8b5f https://share.transistor.fm/s/4cb2675b Our topic of discussion today is a critical one that impacts the world of cardiology and beyond cardiac myosin inhibitors. This cutting-edge area of research has the potential to revolutionize the way we approach cardiac diseases, and our experts are here to shed light on the latest developments, breakthroughs, and implications for patients and athletes alike.

So, whether you're a medical professional, a sports enthusiast, or simply someone interested in the intersection of sports and cardiology, you're in for a treat! Dr. Michael Ayers and Dr. Anjali Owens are here to share their insights, expertise, and passion for this groundbreaking field.

About our Host and Guest:
Dr. Michael Ayers is a sports cardiologist caring for hypertrophic cardiomyopathy patients, a genetic condition causing the thickening of the heart muscle.
Dr. Anjali Owens is a Medical Director, at the Center for Inherited Cardiac Disease and Associate Professor of Medicine (Cardiovascular Medicine) at the Hospital of the University of Pennsylvania

]]> Our topic of discussion today is a critical one that impacts the world of cardiology and beyond cardiac myosin inhibitors. This cutting-edge area of research has the potential to revolutionize the way we approach cardiac diseases, and our experts are here to shed light on the latest developments, breakthroughs, and implications for patients and athletes alike.

So, whether you're a medical professional, a sports enthusiast, or simply someone interested in the intersection of sports and cardiology, you're in for a treat! Dr. Michael Ayers and Dr. Anjali Owens are here to share their insights, expertise, and passion for this groundbreaking field.

About our Host and Guest:
Dr. Michael Ayers is a sports cardiologist caring for hypertrophic cardiomyopathy patients, a genetic condition causing the thickening of the heart muscle.
Dr. Anjali Owens is a Medical Director, at the Center for Inherited Cardiac Disease and Associate Professor of Medicine (Cardiovascular Medicine) at the Hospital of the University of Pennsylvania

]]> Wed, 18 Oct 2023 00:00:00 -0400 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1764 Our topic of discussion today is a critical one that impacts the world of cardiology and beyond cardiac myosin inhibitors. This cutting-edge area of research has the potential to revolutionize the way we approach cardiac diseases, and our experts are here to shed light on the latest developments, breakthroughs, and implications for patients and athletes alike.

So, whether you're a medical professional, a sports enthusiast, or simply someone interested in the intersection of sports and cardiology, you're in for a treat! Dr. Michael Ayers and Dr. Anjali Owens are here to share their insights, expertise, and passion for this groundbreaking field.

About our Host and Guest:
Dr. Michael Ayers is a sports cardiologist caring for hypertrophic cardiomyopathy patients, a genetic condition causing the thickening of the heart muscle.
Dr. Anjali Owens is a Medical Director, at the Center for Inherited Cardiac Disease and Associate Professor of Medicine (Cardiovascular Medicine) at the Hospital of the University of Pennsylvania

]]> No 2023 HCMS Sessions Oral Abstract Presentations 7 7 2023 HCMS Sessions Oral Abstract Presentations full b88b4bf6-d7d1-4b40-a469-b3408db64a13 https://share.transistor.fm/s/85a88e0c You’re listening to In the Thick of It, a podcast from the HCM Society, where we interview experts in the Hypertrophic Cardiomyopathy field, to broaden the awareness of new HCM studies & advancements!

In this episode, Dr. Robyn Bryde and Dr. Bradley Lander will interview each presenting author of the selected abstracts to tell us more about their HCM research. The guests are Dr. Said Alsidawi, Dr. Stuart Campbell, and Dr. Anjali Owens.

These abstract presentations were selected to encore at the 2023 HCMS Scientific Sessions on October 6.  Join us as three brilliant minds unravel the latest breakthroughs within HCM studies. This episode is your gateway to cutting-edge research. Stay tuned for a journey through innovation and discovery in the world of healthcare.

In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.

]]> You’re listening to In the Thick of It, a podcast from the HCM Society, where we interview experts in the Hypertrophic Cardiomyopathy field, to broaden the awareness of new HCM studies & advancements!

In this episode, Dr. Robyn Bryde and Dr. Bradley Lander will interview each presenting author of the selected abstracts to tell us more about their HCM research. The guests are Dr. Said Alsidawi, Dr. Stuart Campbell, and Dr. Anjali Owens.

These abstract presentations were selected to encore at the 2023 HCMS Scientific Sessions on October 6.  Join us as three brilliant minds unravel the latest breakthroughs within HCM studies. This episode is your gateway to cutting-edge research. Stay tuned for a journey through innovation and discovery in the world of healthcare.

In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.

]]> Fri, 06 Oct 2023 11:59:00 -0400 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1662 You’re listening to In the Thick of It, a podcast from the HCM Society, where we interview experts in the Hypertrophic Cardiomyopathy field, to broaden the awareness of new HCM studies & advancements!

In this episode, Dr. Robyn Bryde and Dr. Bradley Lander will interview each presenting author of the selected abstracts to tell us more about their HCM research. The guests are Dr. Said Alsidawi, Dr. Stuart Campbell, and Dr. Anjali Owens.

These abstract presentations were selected to encore at the 2023 HCMS Scientific Sessions on October 6.  Join us as three brilliant minds unravel the latest breakthroughs within HCM studies. This episode is your gateway to cutting-edge research. Stay tuned for a journey through innovation and discovery in the world of healthcare.

In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.

]]> No HCM Exercise Prescription with Dr. Michael Emery 6 6 HCM Exercise Prescription with Dr. Michael Emery full c4d0d815-3803-4947-a340-8a2f53cea350 https://share.transistor.fm/s/a101f5ab Welcome to "In the Thick of It," a podcast by the HCM Society, dedicated to shedding light on the latest developments in Hypertrophic Cardiomyopathy. In this episode, Cardiologist Dr. Robyn Bryde engages in an insightful conversation with Dr. Michael Emery. They delve into the crucial topic of exercise restrictions in HCM, exploring the art of crafting exercise prescriptions, counseling athletes and enthusiasts with HCM, and ensuring their safe participation in sports. Tune in for expert insights into this vital aspect of HCM management.

About our Guest:
Dr. Emery is an associate professor of medicine at the Cleveland Clinic Learner College of Medicine. He’s also the Co-Director of the sports cardiology center at Cleveland Clinic and has a background in exercise physiology.

In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.

]]> Welcome to "In the Thick of It," a podcast by the HCM Society, dedicated to shedding light on the latest developments in Hypertrophic Cardiomyopathy. In this episode, Cardiologist Dr. Robyn Bryde engages in an insightful conversation with Dr. Michael Emery. They delve into the crucial topic of exercise restrictions in HCM, exploring the art of crafting exercise prescriptions, counseling athletes and enthusiasts with HCM, and ensuring their safe participation in sports. Tune in for expert insights into this vital aspect of HCM management.

About our Guest:
Dr. Emery is an associate professor of medicine at the Cleveland Clinic Learner College of Medicine. He’s also the Co-Director of the sports cardiology center at Cleveland Clinic and has a background in exercise physiology.

In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.

]]> Tue, 26 Sep 2023 15:31:38 -0400 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1649 Welcome to "In the Thick of It," a podcast by the HCM Society, dedicated to shedding light on the latest developments in Hypertrophic Cardiomyopathy. In this episode, Cardiologist Dr. Robyn Bryde engages in an insightful conversation with Dr. Michael Emery. They delve into the crucial topic of exercise restrictions in HCM, exploring the art of crafting exercise prescriptions, counseling athletes and enthusiasts with HCM, and ensuring their safe participation in sports. Tune in for expert insights into this vital aspect of HCM management.

About our Guest:
Dr. Emery is an associate professor of medicine at the Cleveland Clinic Learner College of Medicine. He’s also the Co-Director of the sports cardiology center at Cleveland Clinic and has a background in exercise physiology.

In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.

]]> No What's Next for Non-obstructive Hypertrophic Cardiomyopathy 5 5 What's Next for Non-obstructive Hypertrophic Cardiomyopathy full 0cfe7e4c-dd36-4133-b5bd-e8aa82174eef https://share.transistor.fm/s/d720abb8 Today, host Dr. Eli Friedman chats with Dr. Ahmad Masri, of Oregan Health Sciences University Hypertrophic Cardiomyopathy Center. Dr. Friedman and Dr. Masri are good friends and former coworkers, and today they’re talking about finding treatment for patients with non-obstructive Hypertrophic Cardiomyopathy, specifically focusing on drugs on clinical trials and Cardio Mitotrope Ninerafaxstat.

Join us in this gripping episode as we dive into the world of non-obstructive Hypertrophic Cardiomyopathy with two experts who are on a mission to unravel its mysteries. Dr. Friedman and Dr. Masri share their insights on groundbreaking clinical trials and the potential game-changer, Cardio Mitotrope Ninerafaxstats. Together, we'll explore the challenges, the breakthroughs, and how science is paving the way for a brighter future in cardiac care!

In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.

]]> Today, host Dr. Eli Friedman chats with Dr. Ahmad Masri, of Oregan Health Sciences University Hypertrophic Cardiomyopathy Center. Dr. Friedman and Dr. Masri are good friends and former coworkers, and today they’re talking about finding treatment for patients with non-obstructive Hypertrophic Cardiomyopathy, specifically focusing on drugs on clinical trials and Cardio Mitotrope Ninerafaxstat.

Join us in this gripping episode as we dive into the world of non-obstructive Hypertrophic Cardiomyopathy with two experts who are on a mission to unravel its mysteries. Dr. Friedman and Dr. Masri share their insights on groundbreaking clinical trials and the potential game-changer, Cardio Mitotrope Ninerafaxstats. Together, we'll explore the challenges, the breakthroughs, and how science is paving the way for a brighter future in cardiac care!

In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.

]]> Wed, 06 Sep 2023 15:04:54 -0400 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1391 Today, host Dr. Eli Friedman chats with Dr. Ahmad Masri, of Oregan Health Sciences University Hypertrophic Cardiomyopathy Center. Dr. Friedman and Dr. Masri are good friends and former coworkers, and today they’re talking about finding treatment for patients with non-obstructive Hypertrophic Cardiomyopathy, specifically focusing on drugs on clinical trials and Cardio Mitotrope Ninerafaxstat.

Join us in this gripping episode as we dive into the world of non-obstructive Hypertrophic Cardiomyopathy with two experts who are on a mission to unravel its mysteries. Dr. Friedman and Dr. Masri share their insights on groundbreaking clinical trials and the potential game-changer, Cardio Mitotrope Ninerafaxstats. Together, we'll explore the challenges, the breakthroughs, and how science is paving the way for a brighter future in cardiac care!

In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.

]]> No 4. HCM Care Evolution: Building Patient-Centric Excellence, with Lisa Salberg 4 4 4. HCM Care Evolution: Building Patient-Centric Excellence, with Lisa Salberg full 10abc5ac-5421-4fab-8cdf-a69901c46e97 https://share.transistor.fm/s/cd18b67c Today, host Dr. Bradley Lander chats with Lisa Salberg, the founder of the HCMA, the Hypertrophic Cardiomyopathy Association. Since 1996, Lisa has been on a journey to educate, advocate, and support other patients based on her experience with HCM - including medical errors that nearly cost her life, and the death of her sister.

With a heartfelt story and personal experiences of HCM, Lisa shares the importance of creating comprehensive care centers for HCM patients. From the early days of limited understanding and awareness to the present, she highlights the evolution of HCM care, emphasizing the critical role of multidisciplinary approaches. By tuning in, you'll unwrap how HCM centers of excellence strive to provide holistic patient care, optimize treatment strategies, and incorporate mental health support, ultimately aiming to enhance the quality of life for those living with this complex genetic heart condition.


In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.

]]> Today, host Dr. Bradley Lander chats with Lisa Salberg, the founder of the HCMA, the Hypertrophic Cardiomyopathy Association. Since 1996, Lisa has been on a journey to educate, advocate, and support other patients based on her experience with HCM - including medical errors that nearly cost her life, and the death of her sister.

With a heartfelt story and personal experiences of HCM, Lisa shares the importance of creating comprehensive care centers for HCM patients. From the early days of limited understanding and awareness to the present, she highlights the evolution of HCM care, emphasizing the critical role of multidisciplinary approaches. By tuning in, you'll unwrap how HCM centers of excellence strive to provide holistic patient care, optimize treatment strategies, and incorporate mental health support, ultimately aiming to enhance the quality of life for those living with this complex genetic heart condition.


In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.

]]> Wed, 26 Jul 2023 00:00:00 -0400 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1901 Today, host Dr. Bradley Lander chats with Lisa Salberg, the founder of the HCMA, the Hypertrophic Cardiomyopathy Association. Since 1996, Lisa has been on a journey to educate, advocate, and support other patients based on her experience with HCM - including medical errors that nearly cost her life, and the death of her sister.

With a heartfelt story and personal experiences of HCM, Lisa shares the importance of creating comprehensive care centers for HCM patients. From the early days of limited understanding and awareness to the present, she highlights the evolution of HCM care, emphasizing the critical role of multidisciplinary approaches. By tuning in, you'll unwrap how HCM centers of excellence strive to provide holistic patient care, optimize treatment strategies, and incorporate mental health support, ultimately aiming to enhance the quality of life for those living with this complex genetic heart condition.


In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.

]]> No 3. Athletes with HCM: Breakthrough Study for Vigorous Exercise 3 3 3. Athletes with HCM: Breakthrough Study for Vigorous Exercise full 2d65c2e3-6e1c-487e-8711-4fdf4a42b302 https://share.transistor.fm/s/374aef93 Today, cardiologist Dr. Robyn Bryde interviews Dr. Matthew Martinez, the Director of Sports Cardiology and Hypertrophic Cardiomyopathy at Morristown Medical Center in New Jersey. Recorded from the Care of the Athletic Heart Conference, they discuss the effects of vigorous exercise on patients with hypertrophic cardiomyopathy (HCM). Historically, patients with HCM were advised to restrict exercise, but recent studies suggest that exercise may not worsen the condition. Dr. Martinez presents findings from a groundbreaking study involving 76 elite athletes with HCM, highlighting the importance of shared decision-making and expert consultation in developing exercise plans for these patients.

In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.

]]> Today, cardiologist Dr. Robyn Bryde interviews Dr. Matthew Martinez, the Director of Sports Cardiology and Hypertrophic Cardiomyopathy at Morristown Medical Center in New Jersey. Recorded from the Care of the Athletic Heart Conference, they discuss the effects of vigorous exercise on patients with hypertrophic cardiomyopathy (HCM). Historically, patients with HCM were advised to restrict exercise, but recent studies suggest that exercise may not worsen the condition. Dr. Martinez presents findings from a groundbreaking study involving 76 elite athletes with HCM, highlighting the importance of shared decision-making and expert consultation in developing exercise plans for these patients.

In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.

]]> Wed, 12 Jul 2023 12:00:00 -0400 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 783 Today, cardiologist Dr. Robyn Bryde interviews Dr. Matthew Martinez, the Director of Sports Cardiology and Hypertrophic Cardiomyopathy at Morristown Medical Center in New Jersey. Recorded from the Care of the Athletic Heart Conference, they discuss the effects of vigorous exercise on patients with hypertrophic cardiomyopathy (HCM). Historically, patients with HCM were advised to restrict exercise, but recent studies suggest that exercise may not worsen the condition. Dr. Martinez presents findings from a groundbreaking study involving 76 elite athletes with HCM, highlighting the importance of shared decision-making and expert consultation in developing exercise plans for these patients.

In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.

]]> No 2. Obstructive Hypertrophic Cardiomyopathy: Survival in Patients 65 and Older 2 2 2. Obstructive Hypertrophic Cardiomyopathy: Survival in Patients 65 and Older full b394ace5-e162-45bc-9dde-e8acea6aa1cf https://share.transistor.fm/s/1fd70305 On today's episode, professor of medicine and director of the HCM Center at Westchester Medical Center in New York, Dr. Srihari Naidu, speaks with Haslam Family Endowed Chair in Cardiovascular Medicine, Dr. Milind Desai. Dr. Desai has come today to discuss an article he wrote for the Journal of the American College of Cardiology, which looks at the long-term outcomes of septal reduction therapies in Medicare patients with obstructive hypertrophic cardiomyopathy.

In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.

]]> On today's episode, professor of medicine and director of the HCM Center at Westchester Medical Center in New York, Dr. Srihari Naidu, speaks with Haslam Family Endowed Chair in Cardiovascular Medicine, Dr. Milind Desai. Dr. Desai has come today to discuss an article he wrote for the Journal of the American College of Cardiology, which looks at the long-term outcomes of septal reduction therapies in Medicare patients with obstructive hypertrophic cardiomyopathy.

In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.

]]> Wed, 28 Jun 2023 12:44:56 -0400 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1438 On today's episode, professor of medicine and director of the HCM Center at Westchester Medical Center in New York, Dr. Srihari Naidu, speaks with Haslam Family Endowed Chair in Cardiovascular Medicine, Dr. Milind Desai. Dr. Desai has come today to discuss an article he wrote for the Journal of the American College of Cardiology, which looks at the long-term outcomes of septal reduction therapies in Medicare patients with obstructive hypertrophic cardiomyopathy.

In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.

]]> No 1. Could vigorous exercise be safe for persons with HCM? 1 1 1. Could vigorous exercise be safe for persons with HCM? full 5c25565f-3f2d-439b-ae98-0d021cff56c5 https://share.transistor.fm/s/7275bf5e Learn more here in the first episode of In the Thick of It by HCMS.  Special thanks to Dr. Rachel Lampert and the LIVE-HCM investigators for this important study!

View Episode 1 slides

In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.

]]> Learn more here in the first episode of In the Thick of It by HCMS.  Special thanks to Dr. Rachel Lampert and the LIVE-HCM investigators for this important study!

View Episode 1 slides

In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.

]]> Wed, 28 Jun 2023 12:23:50 -0400 Hypertrophic Cardiomyopathy Medical Society Hypertrophic Cardiomyopathy Medical Society 1076 Learn more here in the first episode of In the Thick of It by HCMS.  Special thanks to Dr. Rachel Lampert and the LIVE-HCM investigators for this important study!

View Episode 1 slides

In the Thick of It is brought to you by the HCM Society, and is produced by Earfluence.

]]> No